Category Archives: Cell Therapy

Hip arthritis 3.5 years after stem cell therapy by Harry Adelson, N.D.
Bobby describes his outcome 3.5 years after stem cell therapy for his arthritic hip by Harry Adelson, N.D. http://www.docereclinics.com.

By: Harry Adelson, N.D.

Read more from the original source:
Hip arthritis 3.5 years after stem cell therapy by Harry Adelson, N.D. - Video

MIAMI (PRWEB) February 16, 2015

Global Stem Cells Group, Inc. announced an alliance with India-based stem cells company Advancells.com, to share protocols and expand GSCG operations in the India subcontinent with stem cell training and a new treatment center.

Advancells, a pioneer stem cell company with some of the most advanced protocols in the world, focuses on therapeutic applications of regenerative medicine primarily used in stem cells generated from the patients own body. Advancells delivers technologies for safe and effective treatments using their flagship technologies including autologous stem cell therapy from bone marrow and adipose tissue to patients worldwide; Global Stem Cells Group will implement some Advancells technologies in the Regenestem Netowork of worldwide clinics.

Since 2005, Advancells has safely treated thousands of patients for a range of diseases and medical conditions in its various clinics around the globe. Advancells is supported by physicians, stem cell experts and clinical research scientists to continually monitor and improve the effectiveness of its quality management system with excellence and innovation.

"We are pleased to partner with Global Stem Cells Group, to combine our knowledge and expand our ability to bring stem cell medicine to patients worldwide, says Advancells CEO Vipul Jain. I am looking forward to a long and productive alliance.

For more information, visit the Global Stem Cells Group website, email bnovas(AT)stemcellsgroup.com, or call 305-224-1858.

About the Global Stem Cells Group:

Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.

Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.

About the Regenestem Network:

See original here:
Global Stem Cells Group Announces Alliance with Advancells

FAQ Part 1: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS)
The Multiple Sclerosis Society of Canada and the Multiple Sclerosis Scientific Research Foundation have announced a $4.2 million grant in support of the MEse...

By: MSSocietyCanada

View original post here:
FAQ Part 1: MEsenchymal Stem cell therapy for CAnadian MS patients (MESCAMS) - Video

Ras Al Khaimah, UAE (PRWEB) February 12, 2015

Private equity and international research consultancy, Grace Centurys portfolio company, Provia Laboratories, LLC, has announced, just days after the provisional approval of the firms new entrance into the Commonwealth, that Dr. James A. Manganello has been invited to serve on a newly formed pre-clearance team for future entities applying for activity in the Caribbean nation.

The purpose of this team, led by Dr. Desiree Cox, Rhodes Scholar, MD, Ph.D., MPhil, is to provide quality control of the stem cell research and stem cell therapy applications submitted to the Bahamian National Stem Cell Ethics Committee.

"This further demonstrates Provias leadership in this field. Provia has advised pharmaceutical/biotech companies and consulted on multiple initiatives within the National Institutes of Health (NIH) in the field of biobanking for many years now. The team has established itself as a group of thought leaders in the field of bio-banking and stem cell science, Scott Wolf, CEO of Grace Century, commented.

The commonwealth continues to fortify its vision for establishing the nation as a true global force in health care innovations and in the future of the stem cell industry, Wolf added.

I am truly honored to be invited to participate on such an important team, Dr. Manganello said. The Bahamian government, with the help of local businesses, the medical community, and local investors, are trying to attract the best technologies from around the world, and to establish itself as a destination for innovative healthcare. I am excited to do my part to help ensure the highest quality and standards are adhered to.

About Grace Century Grace Century FZ LLC is an International research and private equity consultancy located in Ras Al Khaimah, (north of Dubai) in the United Arab Emirates (UAE). Grace Century specializes in game-changing life science and health related private equity projects.

About Provia Laboratories, LLC Headquartered in Littleton, MA, Provia Laboratories, LLC is a healthcare services company specializing in high-quality bio-banking (the collection, transport, processing and cryogenic storage of biological specimens). Provia Labs offers the Proviasette product range for use in bio-banking environments to improve sample logistics, security and quality. The company manages and promotes its own bio-bank for a dental stem cell banking service, Store-A-Tooth, which gives families the option to store stem cells to protect their childrens future health and take advantage of advances in stem cell therapies. Provia advises industrial, academic and governmental clients on matters related to the preservation of biological specimens for research and clinical use. Provia Labs is a member of ISBER, the International Society for Biological and Environmental Repositories, as well as ESBB, the European, Middle Eastern & African Society for Bio-preservation & Bio-banking. For further information about Provia Labs products and services, call +1 (781) 652-4815 or visit http://www.store-a-tooth.com.

Originally posted here:
Grace Centurys Portfolio Project Board Member Asked to Serve on Bahamian Pre-Clearance Stem Cell Ethics Committee

DUBLIN, Feb .10, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/7zf9mz/cell_therapy) has announced the addition of Jain PharmaBiotech's new report "Cell Therapy - Technologies, Markets and Companies" to their offering.

This report describes and evaluates cell therapy technologies and methods, which have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Role of cells in drug discovery is also described. Cell therapy is bound to become a part of medical practice.

Stem cells are discussed in detail in one chapter. Some light is thrown on the current controversy of embryonic sources of stem cells and comparison with adult sources. Other sources of stem cells such as the placenta, cord blood and fat removed by liposuction are also discussed. Stem cells can also be genetically modified prior to transplantation.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Pharmaceutical applications of stem cells including those in drug discovery are also described. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Cell therapy has applications in a large number of disorders. The most important are diseases of the nervous system and cancer which are the topics for separate chapters. Other applications include cardiac disorders (myocardial infarction and heart failure), diabetes mellitus, diseases of bones and joints, genetic disorders, and wounds of the skin and soft tissues.

Regulatory and ethical issues involving cell therapy are important and are discussed. Current political debate on the use of stem cells from embryonic sources (hESCs) is also presented. Safety is an essential consideration of any new therapy and regulations for cell therapy are those for biological preparations.

The cell-based markets was analyzed for 2014, and projected to 2024.The markets are analyzed according to therapeutic categories, technologies and geographical areas. The largest expansion will be in diseases of the central nervous system, cancer and cardiovascular disorders. Skin and soft tissue repair as well as diabetes mellitus will be other major markets.

The number of companies involved in cell therapy has increased remarkably during the past few years. More than 500 companies have been identified to be involved in cell therapy and 294 of these are profiled in part II of the report along with tabulation of 285 alliances. Of these companies, 160 are involved in stem cells. Profiles of 72 academic institutions in the US involved in cell therapy are also included in part II along with their commercial collaborations. The text is supplemented with 61 Tables and 16 Figures. The bibliography contains 1,200 selected references, which are cited in the text.

Key Topics Covered:

See original here:
Cell Therapy Report 2014-2020 - Technologies, Markets and Companies

Among patients with severe aplastic anemia who received stem cell transplant from an unrelated donor, longer leukocyte (white blood cells) telomere length (a structure at the end of a chromosome) was associated with increased overall survival at 5 years, according to a study in the February 10 issue of JAMA.

Telomeres protect chromosome ends and are essential for maintaining chromosomal stability. Telomere length is a biological marker for cellular aging and the capacity to replicate. Aplastic anemia is a blood disorder where the bone marrow fails to make new blood cells, with one of the causes potentially being defects in telomere biology. Allogeneic (genetically different) hematopoietic (blood marrow) cell transplantation (HCT) is recommended as initial therapy for young patients with acquired severe aplastic anemia when a matched sibling donor is available, according to information in the article.

Shahinaz M. Gadalla, M.D., Ph.D., of the National Cancer Institute, National Institutes of Health, Rockville, M.D. and colleagues evaluated the association between recipient and donor pretransplant leukocyte telomere length with outcomes after unrelated donor allogeneic HCT for 330 patients with severe aplastic anemia. The patients and their unrelated donors had pre-HCT blood samples and other clinical results available at the Center for International Blood and Marrow Transplant Research. Patients underwent HCT between 1989 and 2007 in 84 centers and were followed-up to March 2013. Leukocyte telomere length for both recipient and donor analyses was categorized based on the leukocyte telomere length tertiles (one of three groups) in the donors: long (third tertile) and short (first and second tertiles combined).

The researchers found that longer donor leukocyte telomere length was associated with a higher overall survival (5-year overall survival was 56 percent vs 40 percent in the short donor leukocyte telomere length group). After adjusting for donor age and clinical factors associated with survival following HCT in severe aplastic anemia, the risk of post-HCT all-cause mortality remained approximately 40 percent lower in patients receiving HCT from donors with long vs short leukocyte telomere length. Similar patterns were observed by subtypes of the disease.

There was no association between donor leukocyte telomere length and engraftment or graft-vs-host dis ease (a complication of bone marrow transplantation). Recipient telomere length was not associated with patient overall survival.

"Among patients with severe aplastic anemia who received unrelated donor allogeneic HCT, longer donor leukocyte telomere length was associated with increased overall survival at 3 and 5 years," the authors write. "This observational study suggests that donor leukocyte telomere length may have a role in long-term post-transplant survival."

Editorial: Telomere Length in Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia

"If donor leukocyte telomere length is shown to be associated with survival in other hematopoietic stem cell transplant (HSCT) patient populations, can leukocyte telomere length become one of the factors used to choose the best available donor in matched unrelated donor HSCT (or other types of HSCT)," ask Ayman Saad, M.D., Shin Mineishi, M.D., and Racquel Innis-Shelton, M.D., of the Blood and Marrow Transplantation & Cell Therapy Program, Birmingham, Alabama, in an accompanying editorial.

"The test to determine leukocyte telomere length is widely available, but it is left to each center to determine whether to use it and if so, which test to use. If the procedure is not well standardized, comparison between centers would be difficult or impossible. In addition, leukocyte telomere length may change with aging; thus, leukocyte telomere length results would need to be repeated each time confirmatory typing is performed on the same donor."

"Many questions and issues need to be resolved before leukocyte telomere length can be used as one of the factors to determine the best available donor. Nevertheless, the report by Gadalla et al opens up a new area of scientific investigation. Further studies are warranted to define and optimize the potential role of leukocyte telomere length in selecting donors and improving outcomes for patients with severe aplastic anemia who receive HSCT."

See the article here:
Size of biomarker associated with improved survival following transplantation